tradingkey.logo

Abbott Laboratories

ABT
View Detailed Chart
109.090USD
+0.890+0.82%
Close 02/05, 16:00ETQuotes delayed by 15 min
189.69BMarket Cap
29.25P/E TTM

Abbott Laboratories

109.090
+0.890+0.82%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.82%

5 Days

+2.87%

1 Month

-12.16%

6 Months

-16.04%

Year to Date

-12.93%

1 Year

-15.50%

View Detailed Chart

TradingKey Stock Score of Abbott Laboratories

Currency: USD Updated: 2026-02-04

Key Insights

Abbott Laboratories's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 24 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 133.36.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Abbott Laboratories's Score

Industry at a Glance

Industry Ranking
24 / 206
Overall Ranking
104 / 4519
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Abbott Laboratories Highlights

StrengthsRisks

Abbott Laboratories is an American multinational health care and medical devices corporation headquartered in Abbott Park, Illinois. Founded in 1888 by Chicago physician Wallace Calvin Abbott, the company initially focused on formulating known drugs. Today, it offers medical devices, diagnostics, branded generic medications, and nutritional products. In 2013, Abbott separated its research-based pharmaceuticals division into AbbVie.

Abbott's product lineup includes Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip.

Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 44.33B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 29.13%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 29.13%.
Fairly Valued
The company’s latest PE is 29.01, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.42B shares, increasing 0.28% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 215.00 shares of this stock.

Analyst Rating

Based on 31 analysts
Buy
Current Rating
133.357
Target Price
+21.89%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Abbott Laboratories Info

Abbott Laboratories is an American multinational health care and medical devices corporation headquartered in Abbott Park, Illinois. Founded in 1888 by Chicago physician Wallace Calvin Abbott, the company initially focused on formulating known drugs. Today, it offers medical devices, diagnostics, branded generic medications, and nutritional products. In 2013, Abbott separated its research-based pharmaceuticals division into AbbVie.

Abbott's product lineup includes Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip.

Ticker SymbolABT
CompanyAbbott Laboratories
CEOFord (Robert B)
Websitehttps://www.abbott.com
KeyAI